SNTI · Insider Trading
Senti Biosciences Holdings, Inc. Common Stock
Every open-market purchase and sale reported by SNTI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Timothy K Lu | CEO | F | −157,312 | — |
| 2026-10-23 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | F | −19,953 | — |
| 2026-03-11 | Timothy K Lu | CEO | F | −80,666 | — |
| 2026-03-11 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | F | −10,757 | — |
| 2026-02-03 | Timothy K Lu | CEO | F | −4,191 | — |
| 2026-02-03 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | F | −1,384 | — |
| 2025-07-21 | Bryan Daniel Baum | Director | A | +43,900 deriv. | — |
| 2025-06-27 | Donald F Tang | Director | A | +21,950 deriv. | — |
| 2025-06-27 | James J. Collins | Director | A | +21,950 deriv. | — |
| 2025-06-27 | Brenda Cooperstone | Director | A | +21,950 deriv. | — |
| 2025-06-27 | Edward T Mathers | Director | A | +21,950 deriv. | — |
| 2025-06-27 | Fran Schulz | Director | A | +21,950 deriv. | — |
| 2025-06-27 | Feng Hsiung | Director | A | +21,950 deriv. | — |
| 2025-03-14 | Celadon Partners SPV 24 | 10%+ Owner | C | +9,777,000 | — |
| 2025-03-12 | Bayer World Investments B.V. | 10%+ Owner | C | +8,888,000 | — |
| 2025-03-12 | Scott D Sandell | 10%+ Owner | C | +23,331,000 | — |
| 2025-03-11 | John Harry Cross III | Chief Financial Officer | A | +174,200 deriv. | — |
| 2025-03-11 | Donald F Tang | Director | A | +43,900 deriv. | — |
| 2025-03-11 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | C | +33,000 | +$74.25K |
| 2025-03-11 | Edward T Mathers | Director | A | +43,900 deriv. | — |
| 2025-03-11 | Fran Schulz | Director | A | +43,900 deriv. | — |
| 2025-03-11 | Brenda Cooperstone | Director | A | +43,900 deriv. | — |
| 2025-03-11 | Feng Hsiung | Director | A | +43,900 deriv. | — |
| 2025-03-11 | James J. Collins | Director | A | +43,900 deriv. | — |
| 2025-03-10 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | A | +78,363 | — |
| 2025-03-10 | Timothy K Lu | CEO and Interim PFO and PAO | A | +642,358 | — |
| 2025-02-06 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | Sell | −1,479 | −$6.07K |
| 2025-02-06 | Timothy K Lu | CEO | Sell | −4,467 | −$18.34K |
| 2024-12-11 | Aktiengesellschaft Bayer | 10%+ Owner | Buy | — | — |
| 2024-12-10 | Fran Schulz | Director | A | +12,500 deriv. | — |
| 2024-12-10 | Donald F Tang | Director | A | +12,500 deriv. | — |
| 2024-12-10 | Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | A | +49,533 deriv. | — |
| 2024-07-12 | James J. Collins | Director | A | +62,500 deriv. | — |
| 2024-07-12 | Omid Farokhzad | Director | A | +62,500 deriv. | — |
| 2024-07-12 | Edward T Mathers | Director | A | +62,500 deriv. | — |
| 2024-07-12 | Brenda Cooperstone | Director | A | +62,500 deriv. | — |
| 2024-02-02 | Kanya Rajangam | Chief Medical & Devt. Officer | A | +101,000 | — |
| 2024-02-02 | Deborah Knobelman | Chief Financial Officer | A | +101,000 | — |
| 2024-02-02 | Timothy K Lu | CEO and President | A | +306,000 | — |
| 2023-06-21 | Omid Farokhzad | Director | A | +62,500 deriv. | — |
| 2023-06-21 | Edward T Mathers | Director | A | +62,500 deriv. | — |
| 2023-06-21 | Susan D Berland | Director | A | +62,500 deriv. | — |
| 2023-06-21 | Brenda Cooperstone | Director | A | +62,500 deriv. | — |
| 2023-06-21 | James J. Collins | Director | A | +62,500 deriv. | — |
| 2023-02-02 | Timothy K Lu | CEO and President | A | +630,000 deriv. | — |
| 2023-02-02 | Kanya Rajangam | Chief Medical & Devt. Officer | A | +130,000 deriv. | — |
| 2023-02-02 | Deborah Knobelman | Chief Financial Officer | A | +130,000 deriv. | — |
| 2023-02-02 | Philip J Lee | Chief Technology Officer | A | +195,000 deriv. | — |
| 2022-10-04 | Deborah Knobelman | Chief Financial Officer | A | +30,000 | — |
| 2022-07-20 | Kanya Rajangam | Chief Medical & Devt. Officer | A | +327,750 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Celadon Partners SPV 24 | 10%+ Owner | 9,777,000 | $1.71M |
| Scott D Sandell | 10%+ Owner | 3,775,615 | $661.11K |
| Bayer World Investments B.V. | 10%+ Owner | 2,809,848 | $492.00K |
| Aktiengesellschaft Bayer | 10%+ Owner | 587,848 | $102.93K |
| Timothy K Lu | CEO | 535,110 | $93.70K |
| Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 87,890 | $15.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SNTI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.